Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Brielle Benyon
People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.
Brielle Benyon
Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.
Jessica Skarzynski
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
Kristie L. Kahl
The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.
 
Katie Kosko and Jessica Skarzynski
We've got a sneak peek at what’s inside our Fall 2018 issue.
Brielle Benyon
Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.
Katie Kosko
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.
DEBORAH ABRAMS KAPLAN
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.
Katie Kosko
More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.
Katie Kosko
Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other